NASDAQ:ABUS - Arbutus Biopharma News Headlines

Sign in or create an account to add this stock to your watchlist.
$9.50 -0.05 (-0.52 %)
(As of 09/19/2018 03:12 PM ET)
Previous Close$9.40
Today's Range$9.35 - $9.60
52-Week Range$4.30 - $12.60
Volume3,669 shs
Average Volume303,206 shs
Market Capitalization$531.88 million
P/E Ratio-5.28
Dividend YieldN/A
Beta1.08

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma Corp (ABUS) Short Interest Down 31.2% in AugustArbutus Biopharma Corp (ABUS) Short Interest Down 31.2% in August
www.americanbankingnews.com - September 17 at 1:34 AM
Arbutus Biopharma Corp (ABUS) Expected to Post Quarterly Sales of $230,000.00Arbutus Biopharma Corp (ABUS) Expected to Post Quarterly Sales of $230,000.00
www.americanbankingnews.com - September 13 at 3:36 AM
-$0.40 EPS Expected for Arbutus Biopharma Corp (ABUS) This Quarter-$0.40 EPS Expected for Arbutus Biopharma Corp (ABUS) This Quarter
www.americanbankingnews.com - September 11 at 10:16 AM
Arbutus Biopharma Corp (ABUS) Given Average Rating of "Buy" by AnalystsArbutus Biopharma Corp (ABUS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 3 at 10:49 AM
Arbutus to Participate at the 2018 B. Riley FBR Healthcare ConferenceArbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
finance.yahoo.com - August 28 at 4:57 PM
Arbutus Biopharma Corp (ABUS) Expected to Announce Quarterly Sales of $230,000.00Arbutus Biopharma Corp (ABUS) Expected to Announce Quarterly Sales of $230,000.00
www.americanbankingnews.com - August 27 at 3:37 AM
 Brokerages Anticipate Arbutus Biopharma Corp (ABUS) to Post -$0.40 EPS Brokerages Anticipate Arbutus Biopharma Corp (ABUS) to Post -$0.40 EPS
www.americanbankingnews.com - August 25 at 12:17 PM
More Volatility Ahead For Arbutus BiopharmaMore Volatility Ahead For Arbutus Biopharma
seekingalpha.com - August 17 at 5:36 PM
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making HistoryAlnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
seekingalpha.com - August 13 at 8:13 AM
Arbutus to Present at the 2018 Wedbush PacGrow Healthcare ConferenceArbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 9 at 8:40 AM
Arbutus down 16% after Q2 reportArbutus down 16% after Q2 report
seekingalpha.com - August 3 at 4:34 PM
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call TranscriptArbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 8:23 AM
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate UpdateArbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 2 at 5:32 PM
ContraVir Stock Rose on Clinical Trial Progress ReportContraVir Stock Rose on Clinical Trial Progress Report
finance.yahoo.com - July 24 at 8:38 AM
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
finance.yahoo.com - July 20 at 5:14 PM
Arbutus to Report Second Quarter 2018 Financial ResultsArbutus to Report Second Quarter 2018 Financial Results
globenewswire.com - July 19 at 4:45 PM
Opinion: Harry Boxers three drug stocks to watchOpinion: Harry Boxer's three drug stocks to watch
www.marketwatch.com - July 19 at 4:45 PM
Arbutus: An Extremely Promising RNAi Innovator Hitting Its Growth InflectionArbutus: An Extremely Promising RNAi Innovator Hitting Its Growth Inflection
seekingalpha.com - July 19 at 8:15 AM
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The SunArbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
seekingalpha.com - July 18 at 4:52 PM
Arbutus Presents Corporate Update on Key MilestonesArbutus Presents Corporate Update on Key Milestones
finance.yahoo.com - July 10 at 8:16 AM
B.Riley/FBR Downgrades Arbutus Biopharma (ABUS) to NeutralB.Riley/FBR Downgrades Arbutus Biopharma (ABUS) to Neutral
www.streetinsider.com - July 6 at 8:15 AM
Form 4 Arbutus Biopharma Corp For: Jun 19 Filed by: HENRIQUES RICHARD C JRForm 4 Arbutus Biopharma Corp For: Jun 19 Filed by: HENRIQUES RICHARD C JR
www.streetinsider.com - June 27 at 8:57 AM
Arbutus Biopharma: The Next Big Breakout Biotech?Arbutus Biopharma: The Next Big Breakout Biotech?
seekingalpha.com - June 22 at 5:42 PM
Arbutus Biopharma to Present at First Annual Roivant Pipeline DayArbutus Biopharma to Present at First Annual Roivant Pipeline Day
finance.yahoo.com - June 18 at 8:50 AM
Arbutus appoints David C. Hastings as new Chief Financial OfficerArbutus appoints David C. Hastings as new Chief Financial Officer
seekingalpha.com - June 8 at 8:17 AM
Arbutus Biopharma (ABUS) Announces Appointment of David C. Hastings as New Chief Financial OfficerArbutus Biopharma (ABUS) Announces Appointment of David C. Hastings as New Chief Financial Officer
www.streetinsider.com - June 8 at 8:17 AM
Arbutus Biopharmas (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call TranscriptArbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:42 PM
Arbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/ShareArbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/Share
www.streetinsider.com - May 4 at 5:34 PM
BRIEF-Arbutus Reports Q1 Loss Per Share $0.36BRIEF-Arbutus Reports Q1 Loss Per Share $0.36
www.reuters.com - May 4 at 8:18 AM
Arbutus: 1Q Earnings SnapshotArbutus: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:18 AM
Arbutus Biopharma beats by $0.03, beats on revenueArbutus Biopharma beats by $0.03, beats on revenue
seekingalpha.com - May 3 at 5:25 PM
Arbutus Announces Corporate Update and First Quarter 2018 Financial ResultsArbutus Announces Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:25 PM
Merck Teams With Moderna To Take On One Of The Toughest Targets In CancerMerck Teams With Moderna To Take On One Of The Toughest Targets In Cancer
finance.yahoo.com - May 3 at 5:25 PM
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial ResultsArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 5:14 PM
BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...
www.reuters.com - April 13 at 5:33 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...
globenewswire.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...
globenewswire.com - April 13 at 5:33 PM
Form 8-K Arbutus Biopharma Corp For: Apr 12Form 8-K Arbutus Biopharma Corp For: Apr 12
www.streetinsider.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
finance.yahoo.com - April 12 at 5:39 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic DiseasesArbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
finance.yahoo.com - April 11 at 5:32 PM
Arbutus to Present HBV Data at 2018 EASL Liver MeetingArbutus to Present HBV Data at 2018 EASL Liver Meeting
finance.yahoo.com - March 29 at 8:26 AM
Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMTEdited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMTEdited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Wedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.comWedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM
Wedbush softens view on Arbutus on extended timeline for HBV candidatesWedbush softens view on Arbutus on extended timeline for HBV candidates
seekingalpha.com - March 19 at 5:18 PM
Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To SidelinesWedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines
finance.yahoo.com - March 19 at 5:18 PM
Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.comChardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.com
www.streetinsider.com - March 19 at 8:22 AM
Arbutus Announces Corporate Update and Year-End 2017 Financial ... - GlobeNewswire (press release)Arbutus Announces Corporate Update and Year-End 2017 Financial ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:15 AM
7 Stocks Moving In Wednesdays After-Hours Session | Benzinga - Benzinga7 Stocks Moving In Wednesday's After-Hours Session | Benzinga - Benzinga
www.benzinga.com - March 15 at 8:15 AM
Arbutus Announces Corporate Update and Year-End 2017 Financial ResultsArbutus Announces Corporate Update and Year-End 2017 Financial Results
finance.yahoo.com - March 14 at 7:08 PM
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Featured Article: What is a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel